Cargando…
Proteomic research in sarcomas – current status and future opportunities
Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains unclear. As such, limited clinical progress in prognosis or therapeutic regime...
Autores principales: | Burns, Jessica, Wilding, Christopher P, L Jones, Robin, H Huang, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083238/ https://www.ncbi.nlm.nih.gov/pubmed/31722230 http://dx.doi.org/10.1016/j.semcancer.2019.11.003 |
Ejemplares similares
-
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas
por: Kerrison, William G. J., et al.
Publicado: (2022) -
Current Status and Future Opportunities of Omics Tools in Mycotoxin Research
por: Eshelli, Manal, et al.
Publicado: (2018) -
The proteomic landscape of soft tissue sarcomas
por: Burns, Jessica, et al.
Publicado: (2023) -
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry
por: Milighetti, Martina, et al.
Publicado: (2021) -
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
por: Wilding, Christopher P, et al.
Publicado: (2019)